Payment overview · 2025
General Payments
$140.56
8 reported records · 6 companies
Healthcare provider profile · identity verified
Ferrill R. Conant, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SMITH CENTER, KS · NPI 1487695508
Verified facts
What the public records show
CMS Open Payments records show Ferrill R. Conant, M.D. received $140.56 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.39 | 30.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.67 | 21.1% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $18.96 | 13.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.33 | 13.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.31 | 11.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.90 | 10.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $140.56 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.67 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 432 | 74 |
| Omeprazole | Omeprazole | 336 | 63 |
| Gabapentin | Gabapentin | 258 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 245 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 33 |
| Eliquis | Apixaban | 173 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 171 | 23 |
| Losartan Potassium | Losartan Potassium | 166 | 30 |
| Potassium Chloride | Potassium Chloride | 160 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 28 |
| Donepezil Hcl | Donepezil Hcl | 143 | 19 |
| Lisinopril | Lisinopril | 138 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 28 |
| Furosemide | Furosemide | 116 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 19 |
| Allopurinol | Allopurinol | 112 | 14 |
| Metformin Hcl | Metformin Hcl | 104 | 19 |
| Ezetimibe | Ezetimibe | 97 | 20 |
| Meloxicam | Meloxicam | 86 | 19 |
| Myrbetriq | Mirabegron | 86 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 84 | 13 |
| Metformin Hcl Er | Metformin Hcl | 77 | 13 |
| Famotidine | Famotidine | 76 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 76 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 13 |
| Simvastatin | Simvastatin | 75 | 17 |
| Trazodone Hcl | Trazodone Hcl | 72 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 12 |
| Prednisone | Prednisone | 59 | 40 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 11 |
| Alendronate Sodium | Alendronate Sodium | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 11 |
| Sertraline Hcl | Sertraline Hcl | 50 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Mirtazapine | Mirtazapine | 49 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 46 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 12 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 21 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 12 |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Finasteride | Finasteride | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $140.56 · 8 records | ABBVIE INC. | EVENITY, JARDIANCE, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error